Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eisenmenger's syndrome: current management.

Erika Berman Berman1, Robyn J Barst

  • 1Division of Pediatric Cardiology, Department of Pediatrics, Columbia University, College of Physicians and Surgeons, New York, NY, USA. esb14@columbia.edu

Progress in Cardiovascular Diseases
|November 2, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society.

Circulation·2015
Same author

Long-term safety and efficacy of imatinib in pulmonary arterial hypertension.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2015
Same author

Validation of two predictive models for survival in pulmonary arterial hypertension.

The European respiratory journal·2015
Same author

[New trial designs and potential therapies for pulmonary artery hypertension].

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir·2015
Same author

[Pediatric pulmonary hypertension].

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir·2015
Same author

Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational study.

Chest·2014
Same journal

Socioeconomic inequalities in the association between diet quality and incident cardiovascular diseases: A prospective study in the Netherlands.

Progress in cardiovascular diseases·2026
Same journal

Beyond therapeutic maximalism: Prioritization and personalization in preventive therapies.

Progress in cardiovascular diseases·2026
Same journal

Multimodality imaging of vulnerable plaque: Are we there yet? A multifaceted perspective.

Progress in cardiovascular diseases·2026
Same journal

Beyond LDL-C: Triangulating residual risk via lipoprotein(a), remnant cholesterol, and vascular inflammation.

Progress in cardiovascular diseases·2026
Same journal

COVID-19 and coronary atherosclerosis: Unmasking and accelerating?

Progress in cardiovascular diseases·2026
Same journal

Mavacamten and left ventricular dysfunction in hypertrophic cardiomyopathy with left bundle branch block.

Progress in cardiovascular diseases·2026
See all related articles

Eisenmenger's syndrome causes high pulmonary arterial pressure due to congenital heart defects. While incurable, current management strategies improve patient quality of life.

Area of Science:

  • Cardiology
  • Pulmonology
  • Pediatric Cardiology

Background:

  • Eisenmenger's syndrome is a severe complication of unrepaired congenital heart disease.
  • It involves elevated pulmonary arterial pressure leading to reversed blood flow.
  • This condition results from increased pulmonary vascular resistance.

Purpose of the Study:

  • To review the natural history and pathophysiology of Eisenmenger's syndrome.
  • To discuss current medical and surgical treatment options.
  • To highlight recent advances in patient management.

Main Methods:

  • Literature review of Eisenmenger's syndrome.
  • Analysis of pathophysiology and natural history.
  • Evaluation of existing treatment modalities.

Related Experiment Videos

Main Results:

  • Eisenmenger's syndrome is characterized by pulmonary hypertension and shunting.
  • Untreated, the condition progresses with significant morbidity.
  • Available treatments aim to manage symptoms and improve quality of life.

Conclusions:

  • There is currently no definitive cure for Eisenmenger's syndrome.
  • Advances in management have led to improved quality of life for affected individuals.
  • Further research into novel therapies is warranted.